NCT01438554View on ClinicalTrials.gov

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

August 31, 2018

Conditions
Solid TumorsThyroid CancerSoft-tissue SarcomaCholangiocarcinoma
Interventions
DRUG

Pazopanib

DRUG

GSK1120212

Trial Locations (2)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Novartis

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER